These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 10716599)

  • 1. Development of a lyophilization formulation that preserves the biological activity of the platelet-inducing cytokine interleukin-11 at low concentrations.
    Page C; Dawson P; Woollacott D; Thorpe R; Mire-Sluis A
    J Pharm Pharmacol; 2000 Jan; 52(1):19-26. PubMed ID: 10716599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The improved dissolution and prevention of ampoule breakage attained by the introduction of pretreatment into the production process of the lyophilized formulation of recombinant human Interleukin-11 (rhIL-11).
    Hirakura Y; Kojima S; Okada A; Yokohama S; Yokota S
    Int J Pharm; 2004 Nov; 286(1-2):53-67. PubMed ID: 15501002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a lyophilized formulation of interleukin-2.
    Hora MS; Rana RK; Wilcox CL; Katre NV; Hirtzer P; Wolfe SN; Thomson JW
    Dev Biol Stand; 1992; 74():295-303; discussion 303-6. PubMed ID: 1592178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing storage stability of lyophilized recombinant human interleukin-11 with disaccharide/hydroxyethyl starch mixtures.
    Garzon-Rodriguez W; Koval RL; Chongprasert S; Krishnan S; Randolph TW; Warne NW; Carpenter JF
    J Pharm Sci; 2004 Mar; 93(3):684-96. PubMed ID: 14762907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a stable freeze-dried formulation of recombinant human interleukin-1 receptor antagonist.
    Chang BS; Reeder G; Carpenter JF
    Pharm Res; 1996 Feb; 13(2):243-9. PubMed ID: 8932444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term stabilization of a new freeze-dried and albumin-free formulation of recombinant human interferon alpha 2b.
    Ruiz L; Reyes N; Sotolongo J; Aroche K; Aldana R; Báez R; Hardy E
    PDA J Pharm Sci Technol; 2006; 60(1):72-8. PubMed ID: 17089680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability Studies of a Freeze-Dried Recombinant Human Epidermal Growth Factor Formulation for Wound Healing.
    Santana H; García G; Vega M; Beldarraín A; Páez R
    PDA J Pharm Sci Technol; 2015; 69(3):399-416. PubMed ID: 26048746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significant Drying Time Reduction Using Microwave-Assisted Freeze-Drying for a Monoclonal Antibody.
    Gitter JH; Geidobler R; Presser I; Winter G
    J Pharm Sci; 2018 Oct; 107(10):2538-2543. PubMed ID: 29890173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Freeze drying of human serum albumin (HSA) nanoparticles with different excipients.
    Anhorn MG; Mahler HC; Langer K
    Int J Pharm; 2008 Nov; 363(1-2):162-9. PubMed ID: 18672043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations.
    Roy S; Jung R; Kerwin BA; Randolph TW; Carpenter JF
    J Pharm Sci; 2005 Feb; 94(2):382-96. PubMed ID: 15614819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physical factors affecting the storage stability of freeze-dried interleukin-1 receptor antagonist: glass transition and protein conformation.
    Chang BS; Beauvais RM; Dong A; Carpenter JF
    Arch Biochem Biophys; 1996 Jul; 331(2):249-58. PubMed ID: 8660705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stabilization of a recombinant human epidermal growth factor parenteral formulation through freeze-drying.
    Santana H; Sotolongo J; González Y; Hernández G; Chinea G; Gerónimo H; Amarantes O; Beldarraín A; Páez R
    Biologicals; 2014 Nov; 42(6):322-33. PubMed ID: 25190208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of pH on stability of recombinant botulinum serotype A vaccine in aqueous solution and during storage of freeze-dried formulations.
    Roy S; Henderson I; Nayar R; Randolph TW; Carpenter JF
    J Pharm Sci; 2008 Dec; 97(12):5132-46. PubMed ID: 18399536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting the Stability of Formulations Containing Lyophilized Human Serum Albumin and Sucrose/Trehalose Using Solid-State NMR Spectroscopy.
    Tower CW; Lay-Fortenbery A; Su Y; Munson EJ
    Mol Pharm; 2024 Jul; 21(7):3163-3172. PubMed ID: 38781678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Freeze-Drying of L-Arginine/Sucrose-Based Protein Formulations, Part 2: Optimization of Formulation Design and Freeze-Drying Process Conditions for an L-Arginine Chloride-Based Protein Formulation System.
    Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
    J Pharm Sci; 2015 Dec; 104(12):4241-4256. PubMed ID: 26422647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of freeze-dried albumin-free formulation of recombinant factor VIII SQ.
    Osterberg T; Fatouros A; Mikaelsson M
    Pharm Res; 1997 Jul; 14(7):892-8. PubMed ID: 9244146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new mechanism for decreasing aggregation of recombinant human interferon-gamma by a surfactant: slowed dissolution of lyophilized formulations in a solution containing 0.03% polysorbate 20.
    Webb SD; Cleland JL; Carpenter JF; Randolph TW
    J Pharm Sci; 2002 Feb; 91(2):543-58. PubMed ID: 11835212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A spray freeze dried micropellet based formulation proof-of-concept for a yellow fever vaccine candidate.
    Clénet D; Hourquet V; Woinet B; Ponceblanc H; Vangelisti M
    Eur J Pharm Biopharm; 2019 Sep; 142():334-343. PubMed ID: 31306751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adsorption of endotoxin on glass in the presence of rhIL-11.
    Yokota H; Kiyonaga H; Kaniwa H; Saisho N
    J Pharm Biomed Anal; 2000 Jun; 22(5):757-61. PubMed ID: 10815718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization.
    Hassett KJ; Cousins MC; Rabia LA; Chadwick CM; O'Hara JM; Nandi P; Brey RN; Mantis NJ; Carpenter JF; Randolph TW
    Eur J Pharm Biopharm; 2013 Oct; 85(2):279-86. PubMed ID: 23583494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.